Investing in Life Science

Panel Discussions

Stories that stick: Unmuting the Nordic Biotech Narrative
Nordic biotechs are poised for global impact but often face challenges in crafting compelling narratives that captivate investors, unlike their US counterparts. In one of the panel discussions, emerging entrepreneurs and visionary investors will explore how to transform complex science into powerful, investor-ready stories. Discover strategies to balance scientific rigor with persuasive storytelling, unlocking new opportunities for funding, strategic partnerships, and accelerated growth. This is a must-attend session for the next generation shaping the future of life science.

China – The new M.V.P. in Global Pharma Dealmaking 
China has rapidly emerged as one of the most influential players in global pharma transactions – from licensing deals to cross-border M&A. What does this mean for Nordic biotech and pharma companies, and how should investors view the opportunities and risks?

Join our expert panel as we explore how Chinese dealmaking is reshaping the industry, what attracts Chinese capital and partners to Europe, and how geopolitics, regulation, and competition will shape the next decade of global pharma growth.

The Financing Playbook: Attracting Capital in a Shifting Market

Volatile macro conditions, deflated valuations and tighter capital markets have reshaped the financing landscape for life science companies. Securing capital is tougher, more competitive, and more strategic than ever. Are we in for another cold winter or do we see signals of a positive change in investor appetite? This panel of financing experts will deliver sharp insights on the current trends; who is investing, how to position your company, and which financing strategies actually work in this challenging climate. 

Company showcases

Experience dynamic, concise presentations from pioneering life science innovators, showcasing cutting-edge advancements and transformative trends shaping the industry’s future. Engage directly with these trailblazers in interactive Q&A sessions, gaining exclusive insights to inform your strategic decisions. Don’t miss this premier opportunity to connect, learn, and invest in the next wave of life science innovation.

A Premier Venue

BioStock will host Investing in Life Science – From Seed to Success at the prestigious IVA Conference Centre, nestled in the heart of Stockholm’s historic quarters. This iconic venue seamlessly blends the city’s timeless charm with state-of-the-art facilities, creating an inspiring backdrop for transformative connections. Engage in unparalleled networking and collaboration with leading innovators, investors, and industry experts in a sophisticated setting designed to spark innovation and drive the future of life science.

📍Grev Turegatan 16

Your Global CRO Partner in Clinical Research: TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 40 countries, TFS and its strategic partners provide tailored strategic resourcing solutions and clinical development services in specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. Dedicated to empowering partners and enriching lives, TFS offers flexible solutions that combine global reach with the agility and responsiveness of a mid-sized CRO.

DNB//Back Bay provides healthcare companies with strategic and M&A guidance and execution, licensing and partnering support, a complete range of corporate and investment banking products and services, and full-scale origination and distribution capabilities in global capital markets.

Together, DNB and Back Bay Life Science Advisors hold a unique position bridging the Nordic and US markets, offering support to companies along the full continuum of life science and healthcare.

Potter Clarkson is one of Europe’s leading full-service IP law firms. 

Our sole objective is to help innovators and investors maximise the value of their business or investments by identifying, protecting, exploiting, and enforcing the required IP rights anywhere in the world.

With regards to biotechnology and the life sciences, our team is one of Europe’s largest.  We are fiercely proud of our reputation as the European IP firm of choice for clients of all sizes, from ambitious start-ups and SMEs through to Big Pharma.

Having worked alongside investors in the Nordics, Germany, and the UK for decades we also know to deliver the comprehensive and commercial view of the IP in an investment required to support the best investment decisions.

With more than 90 pct. of all US biotech, pharma & life science companies listed on Nasdaq, we know how to match savvy investors with trail-blazing inventors.

We are here to support your ideas and the next steps to a public offering that keeps you in control while raising capital to ignite your ambition. By the way, if you want to keep your ambition closer to home, Nasdaq in the Nordic is the leading hub for listed biotech and health care companies in Europe, with strong support from investors and innovation communities across the region.

How to join the Nasdaq family? – Read more here.